TOPLINE:

Anti- calcitonin gene-related peptide monoclonal antibodies (mAbs) demonstrated meaningful and sustained effectiveness in reducing monthly migraine days (MMDs) across three consecutive 1-year treatment cycles, but the relevant burden of the disease remained high.

METHODOLOGY:

Researchers conducted a multicentric, open-label and observational, real-world study including 179 patients with migraine (mean age, 51.3 years; 75.4% women) who initiated treatment with mAbs ( erenumab , galcanezumab , or fremanezumab ) between December 2018 and January 2020.

All participants underwent three consecutive 1-year treatment cycles with mAbs (C1: the start of C1 to the end of C1, C2: the start of C2 to the end of C2, and C3: the start of C3 to the end of C3), with each cycle being s

See Full Page